Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

[1]  K. Kirito,et al.  Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels. , 2013, Experimental hematology.

[2]  M. Ramanathan,et al.  Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  G. Cheng,et al.  Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. , 2013, Immunity.

[4]  M. Ramanathan,et al.  Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study , 2013, PloS one.

[5]  Dana Horakova,et al.  Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.

[6]  M. Krumbholz,et al.  B cells and antibodies in multiple sclerosis pathogenesis and therapy , 2012, Nature Reviews Neurology.

[7]  M. Dwyer,et al.  Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.

[8]  T. Frimurer,et al.  Molecular Characterization of Oxysterol Binding to the Epstein-Barr Virus-induced Gene 2 (GPR183)* , 2012, The Journal of Biological Chemistry.

[9]  T. Holmøy,et al.  Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment , 2012, Neurology.

[10]  H. Harbo,et al.  The genetics of multiple sclerosis: an up‐to‐date review , 2012, Immunological reviews.

[11]  A. Cross,et al.  Randomized controlled trial of atorvastatin in clinically isolated syndrome , 2012, Neurology.

[12]  Y. Stierhof,et al.  Human Cytomegalovirus Entry into Dendritic Cells Occurs via a Macropinocytosis-Like Pathway in a pH-Independent and Cholesterol-Dependent Manner , 2012, PloS one.

[13]  G Giovannoni,et al.  The evidence for a role of B cells in multiple sclerosis , 2012, Neurology.

[14]  Robert Zivadinov,et al.  Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis A case-control study , 2012, NeuroImage.

[15]  M. Ramanathan,et al.  Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis , 2011, Journal of the Neurological Sciences.

[16]  Hongye Luo,et al.  Statins for multiple sclerosis. , 2011, The Cochrane database of systematic reviews.

[17]  F. Barkhof,et al.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.

[18]  M. Ramanathan,et al.  Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis , 2011, Journal of Neuroinflammation.

[19]  J. Cyster,et al.  EBI2 Guides Serial Movements of Activated B Cells and Ligand Activity Is Detectable in Lymphoid and Nonlymphoid Tissues , 2011, The Journal of Immunology.

[20]  L. Karlsson,et al.  Oxysterols direct B-cell migration through EBI2 , 2011, Nature.

[21]  P. Schultz,et al.  Oxysterols direct immune cell migration via EBI2 , 2011, Nature.

[22]  G. Hansson,et al.  The immune system in atherosclerosis , 2011, Nature Immunology.

[23]  M. Ramanathan,et al.  Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients , 2011, PloS one.

[24]  E. Liberopoulos,et al.  Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. , 2010, Atherosclerosis.

[25]  J. Lünemann,et al.  Elevated Epstein–Barr virus‐encoded nuclear antigen‐1 immune responses predict conversion to multiple sclerosis , 2010, Annals of neurology.

[26]  C. Crumpacker,et al.  Cytomegalovirus Infection Causes an Increase of Arterial Blood Pressure , 2009, PLoS pathogens.

[27]  J. Knight,et al.  Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D , 2009, PLoS genetics.

[28]  G. Ebers,et al.  The genetics of clinical outcome in multiple sclerosis , 2008, Journal of Neuroimmunology.

[29]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[30]  M. Landini,et al.  Human Cytomegalovirus Differentially Controls B Cell and T Cell Responses through Effects on Plasmacytoid Dendritic Cells1 , 2007, The Journal of Immunology.

[31]  R. Longnecker,et al.  Cholesterol is critical for Epstein-Barr virus latent membrane protein 2A trafficking and protein stability. , 2007, Virology.

[32]  L. Miosge,et al.  Essential role of membrane cholesterol in accelerated BCR internalization and uncoupling from NF-κB in B cell clonal anergy , 2006, The Journal of experimental medicine.

[33]  O. Kantarci,et al.  Epidemiology and natural history of multiple sclerosis: new insights , 2006, Current opinion in neurology.

[34]  J. Monroe,et al.  Membrane Cholesterol Content Accounts for Developmental Differences in Surface B Cell Receptor Compartmentalization and Signaling* , 2005, Journal of Biological Chemistry.

[35]  J. Cohen,et al.  HMG CoA reductase inhibitors (statins) to treat Epstein–Barr virus-driven lymphoma , 2005, British Journal of Cancer.

[36]  V. Durkalski,et al.  Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.

[37]  J. Cohen,et al.  Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Barnett,et al.  Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.

[39]  A. Branzi,et al.  Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells , 2004, Circulation.

[40]  R. Longnecker,et al.  Cholesterol-dependent infection of Burkitt's lymphoma cell lines by Epstein-Barr virus. , 2003, The Journal of general virology.

[41]  R. Pedrosa,et al.  Therapeutic potential of lovastatin in multiple sclerosis , 2003, Journal of Neurology.

[42]  S. Yusuf,et al.  Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003, Circulation.

[43]  B. Horne,et al.  Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease , 2003, Circulation.

[44]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[45]  A. Szkaradkiewicz,et al.  Cytomegalovirus infection and atherogenesis. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[46]  R. Rudick,et al.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS , 2001, Neurology.

[47]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[48]  A. Folsom,et al.  A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. , 2000, Archives of internal medicine.

[49]  M. Gerritsen,et al.  Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. , 1997, Circulation research.

[50]  G. Jahn,et al.  Cytomegalovirus cell tropism. , 2008, Current topics in microbiology and immunology.

[51]  K. Lemström,et al.  Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. , 1994, The American journal of pathology.